294 filings
Page 4 of 15
6-K
z4crgireuq3j0shg
29 Mar 19
Primary Document
8:53am
6-K
2f043j4i4e7u3kj
20 Mar 19
To Begin Trading on the OTC Markets System
12:00am
6-K
ycxpsz s7pyecqx7w
4 Mar 19
Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
7:40am
6-K
rgyup1whrp
4 Mar 19
Primary Document
7:13am
6-K
u6jfo3in3f1qrdgomi
1 Mar 19
Primary Document
12:00am
6-K
f699l035
22 Feb 19
Primary Document
5:24pm
6-K
g3u8 f26mev08
20 Feb 19
Primary Document
8:06am
6-K
ipi2i4bfm 9y6axcx5
4 Feb 19
Intellipharmaceutics Appoints New Chief Financial Officer
5:10pm
6-K
lrcus5bdfb459stw55y
28 Jan 19
Intellipharmaceutics Receives Extension from Nasdaq Hearings Panel
5:06pm
6-K
zxx4b
7 Jan 19
Intellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products
8:09am
6-K
8ljtpe ir
5 Dec 18
Primary Document
12:00am
6-K
5lj y5nur
27 Nov 18
Intellipharmaceutics Announces FDA Final Approval of Generic Effexor® XR
5:14pm
6-K
9qntqmyyjf8hr7
27 Nov 18
Primary Document
8:10am
6-K
xnvj1p8
26 Nov 18
Intellipharmaceutics Announces Receipt of Nasdaq Notice
9:37pm
6-K
sngynt
21 Nov 18
Primary Document
4:30pm
6-K
6n27uv8s5
21 Nov 18
Exclusive Distribution Agreements in Malaysia and Vietnam
12:00am
6-K
mu70bc8h9ahrtt0crt
6 Nov 18
Intellipharmaceutics Announces Resignation of Chief Financial Officer
12:00am
6-K
6e60qg9f
26 Oct 18
Primary Document
8:06am
6-K
0l5p7pzy8446xcfn7
17 Oct 18
Primary Document
2:49pm
6-K
ufyd 6xub099p
16 Oct 18
Intellipharmaceutics Announces Closing of US$14.3 Million Underwritten Public Offering
9:16pm